CP 230821

Drug Profile

CP 230821

Latest Information Update: 17 Jan 2007

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hypercholesterolaemia

Most Recent Events

  • 10 Mar 2000 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
  • 10 Mar 2000 No-Development-Reported for Atherosclerosis in USA (Unknown route)
  • 05 Jul 1995 Preclinical development for Hypercholesterolaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top